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ABSTRACT
Protein arginine methyltransferases (PRMTs) medi-
ate the transfer of methyl groups to arginines in pro-
teins involved in signal transduction, transcriptional
regulation and RNA processing. Tumor suppressor
p53 coordinates crucial cellular processes, includ-
ing cell-cycle arrest and DNA repair, in response to
stress signals. Post-translational modifications and
interactions with co-factors are important to regu-
late p53 transcriptional activity. To explore whether
PRMTs modulate p53 function, we generated multi-
ple cell lines in which PRMT1, CARM1 and PRMT5
are inducibly knocked down. Here, we showed
that PRMT5, but not PRMT1 or CARM1, is essential
for cell proliferation and PRMT5 deficiency triggers
cell-cycle arrest in G1. In addition, PRMT5 is
required for p53 expression and induction of p53 tar-
gets MDM2 and p21 upon DNA damage. Importantly,
we established that PRMT5 knockdown prevents
p53 protein synthesis. Furthermore, we found that
PRMT5 regulates the expression of translation initi-
ation factor eIF4E and growth suppression mediated
upon PRMT5 knockdown is independent of p53 but
is dependent on eIF4E. Taken together, we uncov-
ered that arginine methyltransferase PRMT5 is a
major pro-survival factor regulating eIF4E expres-
sion and p53 translation.
INTRODUCTION
The tumor suppressor p53 is one of the most frequently
mutated genes in human cancers and p53 germline muta-
tions are responsible for the high incidence of tumors
found in Li-Fraumeni syndrome patients (1). The p53 pro-
tein functions mainly as a transcription factor regulating
important cellular processes, such as cell proliferation,
cell-cycle arrest, DNA repair and apoptosis in response
to stress signals (2,3). In unstressed conditions, p53 is
maintained at a low level in the cell due to binding of
E3 ubiquitin ligase MDM2 (mouse double minute 2),
which leads to p53 ubiquitination and rapid degradation
by the 26S proteasome (4). In response to DNA damage
and other types of cellular stresses, sensor kinases are
activated and mediate the phosphorylation of p53, which
releases MDM2 and promotes p53 stabilization (5).
The transcriptional activity of p53 at distinct target gene
promoters is further modulated through diverse p53
post-translational modiﬁcations and interactions with
co-factors (6). P53 is one of few non-histone proteins regu-
lated through lysine methylation. Indeed, histone lysine
methyltransferases KMT5, KMT3C and KMT5A methy-
late lysines 372, 370 and 382 in p53C-terminus (7–9).
Lysine methylation enhances or suppresses p53 transcrip-
tional activity depending on the methylation site (10).
Furthermore, our earlier study indicated that protein
methyltransferases, especially arginine methyltransferases,
play a role in diﬀerential target gene regulation by
p53 (11).
Arginine methylation is an important process and
involved in the regulation of gene expression, RNA
metabolism and protein function (12,13). Protein arginine
methyltransferases (PRMTs) use S-adenosyl-L-methionine
as methyl donor to catalyze the transfer of a methyl group
to arginine residues in a variety of proteins, including his-
tones H3 and H4, Stat1 and hnRNPs (12). All PRMTs
catalyze the formation of monomethylated arginines.
In addition, type I PRMTs can mediate the transfer of
a second methyl group to monomethylated arginines
asymmetrically, and type II PRMTs can mediate the
transfer of a second methyl group symmetrically (14).
Most of the 11 PRMTs identiﬁed to date are type I
PRMTs, including PRMT1 and coactivator-associated
arginine methyltransferase-1 (CARM1). Type II PRMTs
are PRMT5, PRMT7 and PRMT9. The methyltransferase
activity of PRMT2, PRMT10 and PRMT11 has yet to be
determined. Although all PRMTs contain a conserved
catalytic core, they varied in length and structure at
N- and C-termini. Several recent studies have found that
methylation of histones H3 and H4 by PRMTs plays an
important role in the regulation of gene expression.
Indeed, methylation on histones H4R3 and H3R17 by
PRMT1 and CARM1, respectively, is involved in nuclear
receptor-mediated transcriptional activation (13,15,16).
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a component of hSWI/SNF and NURD chromatin-
remodeling complexes, mediates transcriptional repression
of cell-cycle regulator and tumor suppressor genes, includ-
ing cyclin E, ST7 and NM23 (17,18). In addition, PRMT5
plays a role in androgen receptor-driven transcription, in
a manner independent of its methyltransferase activity
(19). To date, it remains unclear whether PRMTs
are implicated in the cellular response to stress signals,
such as DNA damage and hypoxia. However, p53 has
been reported to interact with PRMT1 and CARM1
in vivo (20). CARM1 and PRMT1 were suggested to
act as co-activators of p53 involved in methylation of his-
tones surrounding its target gene GADD45. In addi-
tion, methylation of arginines in p53 oligomerization
domain by PRMT5 was recently reported to regulate
p53 function (21).
In this study, we explored the role of selected PRMTs
in p53 tumor suppressive function. We generated multiple
stable MCF7 cell lines, which inducibly express shRNA
targeting PRMT1, CARM1 or PRMT5. We found that
knockdown of PRMT5, but not PRMT1 or CARM1,
induces G1 arrest and inhibits cell proliferation.
Importantly, we also found that PRMT5 knockdown
reduces p53 expression and prevents p53 stabilization in
response to DNA damage, leading to a decreased induc-
tion of p53 target genes MDM2 and p21. Consistent with
this, PRMT5 deﬁciency inhibits mutant p53 expression.
Furthermore, we revealed that PRMT5 is required
for p53 protein synthesis. We showed that PRMT5 knock-
down inhibits the expression of eukaryotic translation
initiation factor 4E (eIF4E), an important mediator of
protein translation and that eIF4E inhibition is responsi-
ble for growth suppression upon PRMT5 knockdown.
Therefore, we suggest that PRMT5, a class II arginine
methyltransferase, plays an essential role for cell survival
through regulating eIF4E expression and p53 translation.
MATERIALS AND METHODS
Reagents
Nutlin-3 was purchased from Cayman Chemical Com-
pany. Anti-glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), anti-p21, anti-MDM2 (SMP14), anti-p53 and
anti-eIF4E antibodies were from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA). Anti-hemagglutinin (HA) and anti-
MDM2 (AB-2) were from Covance (Berkeley, CA) and
EMB Biosciences (San Diego, CA), respectively. Anti-
PRMT5 and anti-CARM1 antibodies were from Upstate
(San Diego, CA). Anti-PRMT1 was from Abcam
(Cambridge, MA). Other reagents were from Sigma (St
Louis, MO).
Plasmids
To generate PRMT5 shRNA vector, oligonucleotides
(50-GAT CCC CAC CGC TAT TGC ACC TTG GAT
TCA AGA GAT CCA AGG TGC AAT AGC GGT
TTT TTG GAA A-30 and 50-AGC TTT TCC AAA
AAA CCG CTA TTG CAC CTT GGA TCT CTT GAA
TCC AAG GTG CAA TAG CGG TGG G-30) were
designed to target PRMT5 nucleotides 1689-1707
(shown in boldface). To generate CARM1 shRNA
vector, oligonucleotides (50-GAT CCC CAC GGC GAG
ATC CAG CGG CAT TCA AGA GAT GCC GCT GGA
TCT CGC CGT TTT TTG GAA A-30 and 50-AGC TTT
TCC AAA AAA CGG CGA GAT CCA GCG GCA TCT
CTT GAA TGC CGC TGG ATC TCG CCG TGG G-30)
were designed to target CARM1 nucleotides 257-275
(shown in boldface). To generate PRMT1 shRNA
vector, oligonucleotides (50-GAT CCC CAG CCC AAC
GCT GAG GAC ATT TCA AGA GAA TGT CCT
CAG CGT TGG GCT TTT TTG GAA A-30 and
50-AGC TTT TCC AAA AAA GCC CAA CGC TGA
GGA CAT TCT CTT GAA ATG TCC TCA GCG TTG
GGC TGG G-30) were designed to target PRMT1 nucleo-
tides 110-128 (shown in boldface). Oligonucleotides were
annealed and cloned into pTER, a PolIII promoter-driven
shRNA expression vector. Resulting plasmids were named
pTER/PRMT5, pTER/CARM1 and pTER/PRMT1,
respectively. To stably express siRNA against p53, the
pBabe-U6-sip53 construct was used as described pre-
viously (22). To transiently knockdown PRMT5, double-
stranded RNA oligos (ACC GCU AUU GCA CCU
UGG AdTdT) and scrambled siRNA were synthesized
by Dharmacon (Chicago, IL).
Cell culture
The MCF7-pTR-7 cell line was generated previously by
transfection of MCF7 cells with pcDNA6 vector that
expresses a tetracycline repressor (11). To generate
MCF7 cell lines that inducibly express PRMT5,
CARM1 and PRMT1 shRNAs, MCF7-pTR-7 cells were
transfected with pTER/PRMT5, pTER/CARM1 or
pTER/PRMT1, and the pBabe vector for puromycin
selection. To generate MCF7 cell lines that stably express
p53 shRNA and inducibly express PRMT5 shRNA,
MCF7-pTR-7 cells were transfected with pBabe-
U6-sip53 and pTER/PRMT5. Individual clones were
screened for inducible knockdown of the target gene by
western blot analysis and two representative clones were
chosen for subsequent studies. Human colon carcinoma
RKO and HCT116 cells, colon adenocarcinoma SW480
cells and glioblastoma T98G cells were obtained from
ATCC (Manassas, VA) and cultured in DMEM
(Invitrogen, Carlsbad, CA) supplemented with 8% fetal
bovine serum (Hyclone, Logan, UT).
Western blot analysis
Cells are washed twice with PBS, re-suspended with 2 
SDS sample buﬀer, incubated at 958C for 5min, and used
for western blot analysis as previously described (23).
Growth rate and colony formation assay
To determine cell growth rate, 1 10
4cells were seeded
per 6-well plate. After 24h, cells were untreated or treated
with tetracycline. At times indicated, cells were collected
and counted using a Coulter cell Counter (Coulter
Corporation). For colony formation assay, cells seeded
at 1 10
3cells per well in a 6-well plate were incubated
in the absence or presence of tetracycline for 10 days.
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with crystal violet for 20min as previously described (24).
DNA histogram analysis
For DNA histogram analysis, 2 10
5cells were seeded
per 90mm-diameter plate and were untreated or treated
with tetracycline for 4 days. Cells were collected and
stained with propidium iodide as previously described,
and examined by ﬂuorescence-activated cell sorter
(FACS Calibur) (25).
[
35S]Methionine labeling
For
35S protein labeling, 0.5 10
6cells were seeded per
90mm-diameter plate, untreated or treated with tetracy-
cline for 3 days. After 2 washes and incubation with
Methionine-free DMEM (Invitrogen, Carlsbad, CA) for
3h, cells were incubated with [
35S]methionine-containing
DMEM (50mCi/ml) for 30min (Express
35S protein assay
labeling mix, Perkin Elmer). Cells extracts were prepared
in 0.5% NP-40 lysis buﬀer as described previously (24).
p53 immunoprecipitation and autoradiography
Immunoprecipitation was performed as previously
described (24). [
35S]methionine-labeled cells extracts were
prepared in 0.5% NP-40 lysis buﬀer and p53 was immu-
noprecipitated with an anti-p53 antibody or control rabbit
IgG at 48C overnight. After 4 washes with 0.5% NP-40
lysis buﬀer, immunoprecipitated p53 was resuspended
with 2  SDS sample buﬀer, incubated at 958C for
5min, and used for SDS PAGE. Gels were ﬁxed with
ﬁxation solution (10% acetic acid and 30% methanol),
incubated with Enhancer (Perkin Elmer, Boston, MA)
for 30min and washed three times with distilled water.
Gels were dried using a gel dryer and vacuum pump
(Biorad, Hercules, CA) and exposed to X-ray ﬁlm
at  808C.
Statistical analysis
Unless otherwise stated, all experiments were performed
in triplicates and data are represented as mean   SD.
Two group comparisons were analyzed by two-tailed
Student’s t-test. P-values were calculated, and values
 0.05 were considered signiﬁcant.
RESULTS
Knockdown of PRMT5 inhibits cell proliferation and
induces G1 arrest
To determine whether a deﬁciency in PRMT5 arginine
methyltransferase has an eﬀect on cell proliferation, we
generated MCF7 cell lines, in which PRMT5 is inducibly
knocked down by the tetracycline-inducible shRNA
expression system. Three representative MCF7-PRMT5-
KD cell lines, MCF7-PRMT5-KD-41/-62/-72, along with
parental MCF7-pTR-7 cell line, are shown in Figure 1A.
We showed that PRMT5 levels were decreased by 55% in
MCF7-PRMT5-KD-41 cells and 35% in MCF7-PRMT5-
KD-62/-72 cells upon the induction of PRMT5 shRNA
for 4 days. The level of GAPDH was determined as a
loading control. Next, we performed a colony-formation
assay to determine the long-term eﬀect of PRMT5 knock-
down on cell proliferation (Figure 1B). In the parental
MCF7-pTR-7 cell line, tetracycline was not found to
have any eﬀect on MCF7 cell proliferation (Figure 1B,
the ﬁrst column). In contrast, we found that the ability
of MCF7 cells to proliferate and form colonies was clearly
reduced upon knockdown of PRMT5 for 10 days. To
further characterize the short-term impact of PRMT5
knockdown on cell proliferation, we performed an 8-day
growth curve on MCF7-pTR-7 and MCF7-PRMT5-KD-
41/-62/-72 (Figure 1C). We found that there was a signif-
icant decrease in the number of proliferating cells starting
after 4 days of PRMT5 knockdown. Thus, to characterize
the cell-cycle proﬁle of PRMT5 knockdown cells, DNA
histogram assay was performed on MCF7-pTR-7 and
MCF7-PRMT5-KD-41/-62/-72 cells untreated or treated
with tetracycline for 5 days (Figure 1D). We found that
the number of cells in G1 was signiﬁcantly increased upon
knockdown of PRMT5, concomitantly with a decrease in
the number of cells in S phase. Taken together, these data
suggest that PRMT5 is required for cell-cycle progression.
To determine whether the expression of an exogenous
PRMT5 has an eﬀect on MCF7 cell proliferation, we gen-
erated cell lines in which N-terminally HA-tagged PRMT5
is inducibly expressed under the control of a tetracycline-
regulated promoter (data not shown). Next, we performed
colony-formation assays and found that the ability of
MCF7 to proliferate and form colonies was not aﬀected
by PRMT5 expression for 10 days. These results suggest
that overexpression of PRMT5 arginine methyltransferase
alone has no eﬀect on cell proliferation.
Knockdown of CARM1 and PRMT1 has no effect on
cell proliferation
To determine whether a deﬁciency in CARM1 or PRMT1
has an eﬀect on cell proliferation, we generated MCF7 cell
lines that inducibly express shRNA targeting CARM1 or
PRMT1 in the tetracycline-inducible shRNA expression
system. Representative cell lines for the inducible knock-
down of CARM1 (MCF7-CARM1-KD-12/-17) and
PRMT1 (MCF7-PRMT1-KD-6), along with the parental
MCF7-pTR-7 cell line, are shown in Figure 2A. We found
that levels of CARM1 and PRMT1 were decreased by at
least 50% upon induction of their respective shRNA for 4
days. Next, we performed a colony-formation assay to
determine the long-term eﬀect of CARM1 and PRMT1
knockdown on cell proliferation (Figure 2B). We found
that the ability of MCF7-CARM1-KD-12/-17 cells to
proliferate was only slightly attenuated upon knockdown
of CARM1 for 10 days. Similarly, the proliferation of
MCF7-PRMT1-KD-6 cells was slightly decreased upon
knockdown of PRMT1. We further characterized this
eﬀect and found that the total number of colonies was
not aﬀected by knockdown of CARM1 or PRMT1.
In addition, we found that the number of small colonies
(less than 1mm in diameter) was not signiﬁcantly aﬀected
by knockdown of CARM1 or PRMT1 (Figure 2C).
Since CARM1 and PRMT1 belong to type I PRMTs,
they may have redundant eﬀects on cell proliferation.
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PRMT1-KD-5/-9, in which shRNA targeting both
CARM1 and PRMT1 are inducibly expressed
(Figure S1A). To determine whether knockdown of both
PRMTs has an eﬀect on cell proliferation, we performed
colony-formation assays (Figure S1B). We found that
there was only a slight decrease in cell proliferation
upon knockdown of CARM1 and PRMT1. However,
the number of colonies was not signiﬁcantly aﬀected by
deﬁciency in CARM1 and PRMT1 (Figure S1C).
To address whether CARM1 and PRMT1 knockdown
has a short-term impact on cell proliferation, we per-
formed a 9-day growth curve analysis (data not shown).
We found that knockdown of CARM1 and PRMT1
had no eﬀect on the growth rate of MCF7 cells. Taken
together, these data suggest that PRMT1 and CARM1 do
not play an essential role in cell-cycle progression.
PRMT5 is required for both wild-type p53 and mutant
p53 expression
To investigate whether PRMT5 modulates p53 levels
and tumor suppressive function, MCF7-pTR-7 and
MCF7-PRMT5-KD-41 were pretreated with tetracycline
for 3 days, followed by treatment with doxorubicin,
a DNA damage agent, for 6, 12 or 24h. Western blot
Figure 1. PRMT5 is required for G1-S transition. (A) Generation of MCF7 cell lines inducibly expressing PRMT5 shRNA. Levels of PRMT5 and
GAPDH were assayed in MCF7-pTR-7 and MCF7-PRMT5-KD-41/-62/-72 cells cultured in the absence ( ) or presence (+) of tetracycline for 4
days. (B) PRMT5 is required for colony formation. MCF7-pTR-7 and MCF7-PRMT5-KD-41/-62/-72 cells were cultured in the absence or presence
of tetracycline for 10 days. (C) PRMT5 is required for cell proliferation. Growth rate of MCF7-pTR-7 and MCF7-PRMT5-KD-41/-62/-72 cells
cultured in the absence or presence of tetracycline over a 8-day period. The average S.D. of triplicates was plotted, and the data is representative
of three independent experiments. P-values were  0.005 (comparison upon induction for 8 days). (D) Deﬁciency in PRMT5 induces G1 arrest.
MCF7-PRMT5-KD-41/-62/-72 cells were uninduced or induced to knockdown PRMT5 for 5 days. The percentage of cells in each phase of the
cell cycle was quantiﬁed by FACS analysis. The average SEM of three independent experiments is shown. P-values were  0.01 (comparison of cells
numbers in G1).
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MDM2, p21 and GAPDH (Figure 3A). We showed that
in MCF7-pTR-7 cells, doxorubicin stabilized endogenous
p53 after 6h treatment, which resulted in induction of p53
target genes, MDM2 and p21 (Figure 3A, compare lanes 1
and 3). A more pronounced eﬀect on p53, MDM2 and p21
was detected after treatment with doxorubicin for 12
or 24h (Figure 3A, compare lane 3 with lanes 5 and 7).
In addition, we showed that tetracycline had no eﬀect on
p53 stabilization and induction of MDM2 or p21 upon
doxorubicin treatment (Figure 3A, compare lanes 1, 3, 5
and 7 with lanes 2, 4, 6 and 8, respectively). As expected, a
marked decrease in PRMT5 (by  45%) was detected in
PRMT5 knockdown MCF7 cells upon induction of
PRMT5 shRNA for 3 days (Figure 3A, compare lanes
9, 11, 13 and 15 with lanes 10, 12, 14 and 16, respectively).
Interestingly, we also found that PRMT5 knockdown
decreased (by 10%) p53 stabilization in the ﬁrst 6h, fol-
lowing treatment with doxorubicin (Figure 3A, compare
lanes 11 and 12). In addition, a more pronounced eﬀect
on p53 stabilization was detected following treatment
with doxorubicin for 12h (30% decrease) or 24h (32%
decrease) (Figure 3A, compare lanes 13 and 15 with
lanes 14 and 16, respectively). Importantly, we showed
that the decreased p53 stabilization upon PRMT5 knock-
down led to a decrease in induction of MDM2 (by 40%)
and p21 (by 60%) after 24h doxorubicin treatment.
Furthermore, we found that knockdown of PRMT5 had
similar eﬀects on p53 stabilization and its transcriptional
activity in response to treatment with camptothecin,
another DNA damage agent and Nutlin-3, a MDM2
inhibitor (data not shown). Taken together, our data sug-
gest that arginine methyltransferase PRMT5 is required
for eﬃcient stabilization of p53 and its transcriptional
activity in response to cellular stresses.
To conﬁrm that the regulation of p53 upon PRMT5
knockdown is not cell-type speciﬁc, we examined whether
PRMT5 is required for p53 stabilization in RKO and
HCT116 colon carcinoma cell lines. These cell lines
were transiently transfected with scrambled negative con-
trol siRNA or PRMT5 siRNA for 3 days, followed by
treatment with doxorubicin for 12 and 24h (Figure 3B).
Figure 2. CARM1 and PRMT1 are not essential for cell proliferation. (A) Generation of MCF7 cell lines inducibly expressing CARM1 or PRMT1
shRNA. Levels of CARM1, PRMT1 and Actin were assayed in MCF7-pTR-7, MCF7-CARM1-KD-12/-17 and MCF7-PRMT1-KD-6 cells cultured
in the absence ( ) or presence (+) of tetracycline for 4 days. (B) CARM1 or PRMT1 are not required for colony formation. MCF7-pTR-7, MCF7-
CARM1-KD-12/-17 and MCF7-PRMT1-KD-6 cells were cultured in the absence or presence of tetracycline for 10 days. (C) Quantiﬁcation of the
number of colonies shown in (B). The percentage of colonies with a diameter <1mm (left panel) or >1mm (right panel) was calculated in three
representative areas for each cell line. The average SEM was plotted as the percentage of colonies increased or decreased by tetracycline compared
to parental MCF7 cells.
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(by 40%) and HCT116 (by 25%) cells upon induction of
PRMT5 siRNA for 3 days (Figure 3B, compare lanes 1
and 7 with lanes 2 and 8, respectively). Interestingly, we
found that PRMT5 knockdown also decreased p53 stabi-
lization in RKO (by 35%) and HCT116 (by 25%) cells
following treatment with doxorubicin for 12 and 24h
(Figure 3B, compare lanes 3, 5, 9 and 11 with lanes 4, 6,
10 and 12, respectively). Together, these results suggest
that PRMT5 is required for eﬃcient stabilization of p53
in response to cellular stresses in multiple cell lines.
High expression of mutant p53 is frequently found
in human tumors and contributes to tumorigenesis.
To determine whether a deﬁciency in PRMT5 has
an eﬀect on mutant p53 expression, SW480 colon adeno-
carcinoma and T98G glioblastoma cell lines were treated
with scrambled siRNA or PRMT5 siRNA for 3 days
(Figure 3C). As expected, a decrease in PRMT5 was
detected in SW480 (by 34%) and T98G (by 28%)
cells upon induction of PRMT5 siRNA (Figure 3C, com-
pare lanes 1 and 3 with lanes 2 and 4, respectively).
Interestingly, we found that PRMT5 knockdown
decreased mutant p53 expression in SW480 (by 38%)
and T98G (by 30%) cells. These data revealed that simi-
larly to wild-type p53, mutant p53 expression is regulated
by PRMT5.
To investigate whether CARM1 or PRMT1 regulates
p53 stability and transcriptional activity, MCF7-
CARM1-KD-12 and MCF7-PRMT1-KD-6 were pre-
treated with tetracycline for 3 days, followed by treatment
with doxorubicin for 3, 6 or 12h (Figure S2A). Here,
we showed that CARM1 knockdown had little, if any,
eﬀect on p53 stabilization and MDM2 induction upon
doxorubicin treatment (Figure S2A, compare lanes 3, 5
and 7 with lanes 4, 6 and 8). We also found that
PRMT1 knockdown only slightly decreased p53
Figure 3. PRMT5 is required for eﬃcient p53 stabilization and transcriptional activity in multiple cell lines. (A) Cells extracts were prepared from
MCF7-pTR-7 and MCF7-PRMT5-KD-41 cells uninduced ( ) or induced (+) to knockdown PRMT5 for 3 days, and then untreated or treated with
0.35mM doxorubicin for 6, 12 or 24h. (B) Cells extracts were prepared from RKO and HCT116 cells transiently transfected with scrambled control
siRNA ( ) or PRMT5 siRNA (+) for 3 days, and then untreated or treated with 0.35mM doxorubicin for 12 or 24h. (C) Cells extracts were
prepared from SW480 and T98G cells transiently transfected with scrambled control siRNA ( ) or PRMT5 siRNA (+) for 3 days. The data is
representative of two independent experiments. Levels of PRMT5, p53, MDM2, p21 and GAPDH were detected by western blot analysis.
4970 Nucleic Acids Research, 2009, Vol. 37,No. 15stabilization upon treatment with doxorubicin for 6h
(Figure S2A, compare lanes 13 and 14). However, simi-
larly to CARM1 knockdown, PRMT1 knockdown had no
eﬀect on p53 stabilization and MDM2 induction upon
doxorubicin treatment for 12h (Figure S2A, compare
lanes 15 and 16).
To address whether knockdown of both CARM1 and
PRMT1 regulates p53, MCF7-CARM1-PRMT1-KD-5/-9
were pretreated with tetracycline for 3 days, followed by
treatment with doxorubicin for 3, 6 or 12h (Figure S2B).
We found that knockdown of both CARM1 and PRMT1
had little if any eﬀect on p53 stabilization and MDM2
induction upon doxorubicin treatment (Figure S2B, com-
pare lanes 3, 5, 7, 11, 13 and 15 with lanes 4, 6, 8, 12, 14
and 16, respectively). Taken together, these results suggest
that CARM1 and PRMT1 do not play a major role in p53
stability and transcriptional activity in response to DNA
damage.
PRMT5 knockdown inhibits cell proliferation in a
p53-independent manner
The tumor suppressor p53 is a major regulator of cell
proliferation. Thus, we wanted to determine whether p53
plays a role in the inhibition of cell proliferation induced
upon PRMT5 knockdown. To do this, MCF7 cell lines
were generated, in which p53 is stably knocked down and
PRMT5 is inducibly knocked down. Three representative
cell lines, MCF7-PRMT5-KD/p53-KD-3/-11/-25, along
with MCF7-PRMT5-KD-41 cell line, are shown in
Figure 4A. We found that in all three MCF7-PRMT5-
KD/p53-KD cell lines, p53 levels were undetectable
(Figure 4A, p53 panel, compare lanes 1–2 with lanes
3–8). As expected, a marked decrease (by  70%) in
PRMT5 was detected upon tetracycline treatment for 3
days (Figure 4A, compare lanes 1, 3, 5 and 7 with lanes
2, 4, 6 and 8, respectively). In addition, we showed that in
MCF7-PRMT5-KD-41 cell line, basal p53 levels were
decreased (by 20%) upon PRMT5 knockdown
(Figure 4A, compare lanes 1 and 2). Next, we performed
a colony formation assay to determine the long-term eﬀect
of p53 knockdown on cell proliferation (Figure 4B).
We found that p53 knockdown has no eﬀect on the inhi-
bition of cell proliferation induced upon PRMT5 knock-
down in MCF7-PRMT5-KD/p53-KD cell lines. Next, we
performed an 8-day growth curve on MCF7-PRMT5-
KD-41 and MCF7-PRMT5-KD/p53-KD-3/-11/-25
(Figure 4C). We found that the decrease in number of
proliferating cells upon PRMT5 knockdown was similar
between MCF7-PRMT5-KD-41 (48% decrease) and
Figure 4. Knockdown of PRMT5 inhibits cell proliferation in a p53-independent manner. (A) Generation of MCF7 cell lines inducibly expressing
PRMT5 shRNA and stably expressing p53 shRNA. Levels of PRMT5, p53 and GAPDH were assayed in MCF7-PRMT5-KD-41 and MCF7-
PRMT5-KD/p53-KD-3/-11/-25 cells cultured in the absence ( ) or presence (+) of tetracycline for 3 days. (B) PRMT5 is required for colony
formation independently of p53. MCF7-PRMT5-KD-41 and MCF7-PRMT5-KD/p53-KD-3/-11/-25 cells were cultured in the absence or presence of
tetracycline for 10 days. The data is representative of two separate experiments performed in triplicate wells. (C) PRMT5 is required for cell
proliferation independently of p53. Growth rate of MCF7-PRMT5-KD-41 and MCF7-PRMT5-KD/p53-KD-3/-11/-25 cells cultured in the absence
or presence of tetracycline over a 8-day period. The average S.D. of triplicates was plotted and the data is representative of two independent
experiments. P-values were  0.01 (comparison upon induction for 8 days).
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decrease). Taken together, these data suggest that
PRMT5 knockdown inhibits cell proliferation in a
p53-independent manner.
PRMT5 knockdown inhibits p53 protein synthesis
To determine the mechanism through which PRMT5
regulates p53, we sought to examine whether PRMT5
knockdown enhances p53 degradation by 26S proteasome.
MCF7-PRMT5-KD-41 cells were uninduced or induced
to knock down PRMT5 for 3 days, followed by treatment
with MG132, a proteasome inhibitor, for 4 or 8h
(Figure 5A). As expected, PRMT5 was eﬃciently knocked
down upon induction of PRMT5 shRNA for 3 days
(Figure 5A, compare lane 1, 3 and 5 with lanes 2, 4 and
6, respectively). Interestingly, we showed that p53 was
stabilized upon treatment with MG132 for 4h (by
2.5-fold) and 8h (by 3-fold) (Figure 5A, compare lanes 1
with lanes 3 and 5). Similarly, p53 levels were increased in
PRMT5 knockdown cells treated with MG132 for 4h
(by 2.7-fold) and 8h (by 2.9-fold) (Figure 5A, compare
lanes 2 with lanes 4 and 6). However, we found that the
knockdown of PRMT5 decreased p53 to a similar extent
in the absence or presence of MG132 (Figure 5A, compare
lanes 1, 3 and 5 with lanes 2, 4 and 6, respectively). To
check whether PRMT5 knockdown regulates p53 degra-
dation in response to DNA damage, MCF7-PRMT5-KD-
41 cells uninduced or induced to knockdown PRMT5 for
3 days were treated with MG132 for 4 or 8h, followed by
doxorubicin treatment for 6h (Figure 5B). Here, we found
that PRMT5 knockdown prevented p53 stabilization
upon treatment with doxorubicin, regardless of the pres-
ence of MG132 (Figure 5B, compare lanes 7, 9 and 11 with
lanes 8, 10 and 12, respectively). Taken together, our data
suggest that PRMT5 regulates p53 degradation indepen-
dently of the 26S proteasome or through a mechanism
upstream of its degradation.
Next, to assess whether PRMT5 regulates p53 protein
half-life, MCF7-PRMT5-KD-41 cells were treated with
cycloheximide, a protein synthesis inhibitor. As shown in
Figure 5C, MCF7-PRMT5-KD-41 cells were pretreated
with tetracycline for 3 days, followed by doxorubicin
treatment for 6h, and then treatment with cycloheximide
for 30min to up to 210min. Western blot analysis was
performed to measure levels of PRMT5, p53 and
GAPDH (Figure 5C). As expected, we showed that in
control and PRMT5 knockdown cells, p53 levels were
similarly decreased upon cycloheximide treatment over
the time course examined. For instance, we found that
in control and PRMT5 knockdown cells, p53 levels were
reduced by 35% upon treatment with cycloheximide for
90min (Figure 5C, p53 panels, compare lanes 1 and 9
with lanes 4 and 12, respectively). Therefore, the half-life
of p53 was similar in the presence or absence of PRMT5.
Then, we wanted to determine whether changes in p53
protein levels upon PRMT5 knockdown were correlated
with changes in p53 transcript levels. To address this,
real-time PCR experiments were performed on
MCF7-PRMT5-KD-41 cells pretreated with tetracycline
for 3 days, followed by doxorubicin treatment for 12 or
24h (data not shown). We found that knockdown of
PRMT5 had no eﬀect on p53 transcript levels in untreated
cells and only slightly decreased p53 transcript levels in
cells treated with doxorubicin for 12h. Therefore, our
data suggest that PRMT5 regulates p53 downstream of
its transcription.
To determine whether PRMT5 deﬁciency regulates p53
protein synthesis, we performed [
35S]methionine labeling
on MCF7-PRMT5-KD-41 cells untreated or treated with
tetracycline for 3 days, and p53 levels were determined by
immunoprecipitation. Here, we found that knockdown
of PRMT5 had no eﬀect on overall [
35S]methionine-
labeled proteins levels (Figure 5D, compare lanes 1 and
2). However, we showed that PRMT5 knockdown clearly
decreased levels of newly synthesized p53 proteins
(Figure 5D, compare lanes 5 and 6). Taken together, our
data suggest that PRMT5 regulates p53 translation.
PRMT5 is required for translation initiation factor
4E expression
To further address the mechanism through which PRMT5
regulates p53, we investigated whether PRMT5 regulates
the expression of eukaryotic translation initiation factor
4E (eIF4E). eIF4E is a key component in protein synthesis
and therefore plays an important role in cell proliferation
(26). eIF4E is also a mediator of Akt-mTOR signaling
pathway to promote tumorigenesis (27). As shown in
Figure 6A, MCF7-pTR-7 and MCF7-PRMT5-KD-41
cell lines were pretreated with tetracycline for 3 days, fol-
lowed by doxorubicin treatment for 12 or 24h. Western
blot analysis was performed to measure levels of PRMT5,
eIF4E and GAPDH (Figure 6A). We found that in
MCF7-pTR-7 cells, tetracycline had no eﬀect on eIF4E
expression (Figure 6A, compare lanes 1, 3 and 5 with
lanes 2, 4 and 6, respectively). In addition, treatment
with doxorubicin had no eﬀect on eIF4E expression
(Figure 6A, compare lane 1 with lanes 3 and 5). In con-
trast, we found that in MCF7-PRMT5-KD-41, PRMT5
knockdown induced a marked decrease (by  40%) in
eIF4E, regardless of the presence of doxorubicin
(Figure 6A, compare lanes 7, 9 and 11, with lanes 8, 10
and 12, respectively). Taken together, these data suggest
that PRMT5 has a role in protein translation through
regulating eIF4E expression.
To further determine the signiﬁcance of eIF4E regula-
tion by PRMT5, we assessed whether eIF4E plays a role in
the short-term regulation of cell proliferation by PRMT5.
To do this, MCF7-PRMT5-KD-41 cells were transfected
with pcDNA3 vector or pcDNA3 vector expressing
Myc-tagged eIF4E for 24h, followed by treatment with
tetracycline for 3 days. Western blot analysis was per-
formed to measure levels of PRMT5, Myc-tagged eIF4E
and GAPDH (Figure 6B). As expected, a clear decrease in
PRMT5 (by  45%) was detected in PRMT5 knockdown
MCF7 cells upon induction of PRMT5 shRNA for 3 days
(Figure 6B, compare lanes 1 and 3 with lanes 2 and 4,
respectively). In addition, exogenous eIF4E expression
was detected in cells transfected with pcDNA3 vector
containing Myc-tagged eIF4E (Figure 6B, compare lanes
1 and 2 with lanes 3 and 4, respectively). Next, the number
4972 Nucleic Acids Research, 2009, Vol. 37,No. 15of proliferating cells was measured, and we found that
knockdown of PRMT5 decreased MCF7 cell proliferation
by 20% after 3 days (Figure 6C). Furthermore, we showed
that eIF4E expression was suﬃcient to prevent short term
inhibition of cell proliferation by PRMT5 knockdown
(Figure 6C). Taken together, these results revealed that
the regulation of cell proliferation by PRMT5 is depen-
dent on eIF4E.
Figure 5. Knockdown of PRMT5 inhibits p53 protein synthesis. (A and B) MCF7-PRMT5-KD-41 uninduced ( ) or induced (+) to knockdown
PRMT5 for 3 days were (A) untreated or treated with 10mM MG132 for 4 or 8h, (B) followed by treatment with doxorubicin for 6h. Cells extracts
were prepared to determine levels of PRMT5, p53, and GAPDH by western blot analysis. (C) MCF7-PRMT5-KD-41 cells were cultured in the
absence or presence of tetracycline for 3 days and then treated with doxorubicin for 6h, followed by treatment with cycloheximide (CHX) for the
indicated times. Levels of PRMT5, p53 and GAPDH were assayed by western blot analysis. (D) PRMT5 knockdown inhibits p53 protein synthesis.
MCF7-PRMT5-KD-41 cells were uninduced ( ) or induced (+) to knockdown PRMT5 for 3 days and [
35S] methionine-labeled for 30min. Whole-
cell extracts and cells extracts immunoprecipitated with rabbit IgG or antibodies against p53 were resolved by SDS-PAGE and autoradiography. The
data is representative of three independent immunoprecipitation experiments.
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PRMTs have been implicated in many essential cellular
processes ranging from gene expression to cell signaling.
However, studies are needed to explore the physiological
signiﬁcance of many novel PRMTs identiﬁed in the last
few years. In addition, there is little information on the
potential interplay between class I and II PRMTs. Here,
we found that class I and class II PRMTs have distinct
roles in cell proliferation. Indeed, we found that two mem-
bers of class I PRMTs, CARM1 and PRMT1, are mini-
mally required for normal cell proliferation. Consistent
with this, a recent report showed that CARM1 is speciﬁ-
cally required for induction of cell-cycle progression by
ERa in response to estrogen (28). It is therefore likely
that similarly to CARM1, PRMT1 plays a role in stimu-
lating cell proliferation in response to hormones or other
signaling molecules.
In contrast to CARM1 and PRMT1, we showed here
that PRMT5, a class II PRMT, is required for normal cell
proliferation. Indeed, we found that PRMT5 regulates
cell-cycle transition from G1 to S phase. PRMT5 is a
well-known co-repressor present in chromatin-remodeling
repressor complexes (17,18). Indeed, constitutive expres-
sion of PRMT5 antisense vector in NIH 3T3 cells was
found to up-regulate numerous genes, including tumor
suppressor ST7 and cell-cycle regulator cyclin E2 (17).
However, speciﬁc target genes involved in PRMT5-
mediated cell proliferation still remain to be determined.
Interestingly, an oncogenic role for PRMT5 has been
supported by studies showing an increased PRMT5 level
associated with gastric and lymphoid cancers (29,30).
Besides its role as transcriptional co-repressor, PRMT5
is involved in many other cellular processes. Indeed,
PRMT5 facilitates myoD-induced muscle diﬀerentiation
by mediating dimethylation of histone H3R8 and recruit-
ment of Brg1-dependent chromatin remodeling enzymes
for gene activation (31). PRMT5 is involved in androgen
receptor-mediated transcriptional activation, in a manner
independent of its methyltransferase activity (19). PRMT5
is also a component of the 20S methylosome and methy-
lates Sm proteins, which are essential proteins for snRNPs
biogenesis and RNA splicing (32,33). Recently, Jansson
et al. (21) reported that p53 activity is regulated by
PRMT5. The authors showed that PRMT5 methylates
p53 at selected arginine residues in p53 oligomerization
domain. In addition, PRMT5 deﬁciency was found to
have multiple eﬀects on p53, such as reduction in p53
levels, nuclear localization, and oligomerization activity.
Consistent with this, we found that deﬁciency in PRMT5
reduces basal p53 levels and p53 transcriptional activity in
Figure 6. PRMT5 knockdown inhibits the expression of translation initiation factor 4E. (A) Knockdown of PRMT5 inhibits eIF4E expression. Cells
extracts were prepared from MCF7-pTR-7 and MCF7-PRMT5-KD-41 cells uninduced ( ) or induced (+) to knockdown PRMT5 for 3 days, and
then untreated or treated with 0.35mM doxorubicin for 12 or 24h. Levels of PRMT5, eIF4E and GAPDH were detected by western blot analysis.
(B) MCF7-PRMT5-KD-41 cells were transfected with pcDNA3 or pcDNA3 vector expressing Myc-tagged eIF4E for 24h, followed by treatment
with tetracycline for 3 days. Levels of PRMT5, Myc-tagged eIF4E, and GAPDH were detected by western blot analysis. (C) eIF4E expression
attenuates the inhibition of cell proliferation by PRMT5 knockdown. Cells were collected and counted by Coulter counter. The average SEM of
triplicates was plotted as percentage of cells compared to untreated cells.
4974 Nucleic Acids Research, 2009, Vol. 37,No. 15response to DNA damage. Furthermore, we revealed that
PRMT5 regulates p53 protein synthesis. Studies have
reported the regulation of p53 mRNA translation by ribo-
somal proteins, such as L26, and nucleolin although the
mechanisms involved are still poorly understood (34–36).
Here, we found that PRMT5 regulates the expression of
eIF4E, a major component of the translation machinery
involved in the mRNA-ribosome-binding step of protein
synthesis. Indeed, eIF4E is a potent oncogene, which was
previously shown to promote malignant transformation
in vitro and human cancer formation (37,38). Indeed,
cell proliferation mediated by PRMT5 was dependent on
eIF4E, but independent of p53. We speculate that eIF4E is
involved in regulating key growth-promoting factors at
the translational level. However, in response to stress sig-
nals, PRMT5, likely through eIF4E regulation, plays an
important role in providing suﬃcient p53 activation to
induce pro-survival mechanisms, such as cell-cycle arrest
and DNA repair, to ultimately limit the extent of damage
to DNA. Taken together, our study revealed that the argi-
nine methyltransferase PRMT5 is a pro-survival factor,
which regulates cell proliferation in unstressed conditions
and mediates eﬃcient p53 response to protect against
cellular stresses.
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